

Edgar Filing: ICU MEDICAL INC/DE - Form 10-Q

Exchange Act.

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

Class Outstanding at April 30, 2018

Common 20,317,014

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes No

ICU MEDICAL, INC. AND SUBSIDIARIES

Form 10-Q

March 31, 2018

Table of Contents

PART I. Financial Information	Page Number
Item 1. Financial Statements (Unaudited)	
Condensed Consolidated Balance Sheet, at March 31, 2018 and December 31, 2017	<u>3</u>
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2018 and 2017	<u>4</u>
Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2018 and 2017	<u>5</u>
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017	<u>6</u>
<u>Notes to Condensed Consolidated Financial Statements</u>	<u>8</u>
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>27</u>
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	<u>39</u>
Item 4. <u>Controls and Procedures</u>	<u>39</u>
<u>PART II. Other Information</u>	
Item 1. <u>Legal Proceedings</u>	<u>39</u>
Item 1A. <u>Risk Factors</u>	<u>40</u>
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>40</u>
Item 6. <u>Exhibits</u>	<u>41</u>
<u>Signature</u>	<u>42</u>

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value data)

	March 31, 2018 (Unaudited)	December 31, 2017 (1)
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$254,536	\$ 290,072
Short-term investment securities	14,180	10,061
TOTAL CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES	268,716	300,133
Accounts receivable, net of allowance for doubtful accounts of \$3,839 at March 31, 2018 and \$3,311 at December 31, 2017	123,477	112,696
Inventories	295,548	288,657
Prepaid income tax	16,111	10,594
Prepaid expenses and other current assets	32,406	41,286
Related-party receivable	132,272	98,807
Assets held-for-sale	—	12,489
TOTAL CURRENT ASSETS	868,530	864,662
PROPERTY AND EQUIPMENT, net	407,582	398,684
LONG-TERM INVESTMENT SECURITIES	9,896	14,579
GOODWILL	12,314	12,357
INTANGIBLE ASSETS, net	136,645	143,753
DEFERRED INCOME TAXES	20,073	24,775
OTHER ASSETS	37,702	38,141
TOTAL ASSETS	\$1,492,742	\$ 1,496,951
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable	\$82,195	\$ 78,228
Accrued liabilities	116,448	132,064
TOTAL CURRENT LIABILITIES	198,643	210,292
CONTINGENT EARN-OUT LIABILITY	23,000	27,000
OTHER LONG-TERM LIABILITIES	35,074	55,326
DEFERRED INCOME TAXES	1,482	1,487
INCOME TAX LIABILITY	4,592	4,592
COMMITMENTS AND CONTINGENCIES	—	—
STOCKHOLDERS' EQUITY:		
Convertible preferred stock, \$1.00 par value Authorized—500 shares; Issued and outstanding— none	—	—
Common stock, \$0.10 par value — Authorized, 80,000 shares; Issued 20,317 shares at March 31, 2018 and 20,210 shares at December 31, 2017; Outstanding, 20,304 shares at March 31, 2018 and 20,210 shares at December 31, 2017	2,032	2,021
Additional paid-in capital	632,012	625,568
Treasury stock, at cost	(3,176)	—

Edgar Filing: ICU MEDICAL INC/DE - Form 10-Q

Retained earnings	596,829	585,624
Accumulated other comprehensive income (loss)	2,254	(14,959)
TOTAL STOCKHOLDERS' EQUITY	1,229,951	1,198,254
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$1,492,742	\$1,496,951

(1) December 31, 2017 balances were derived from audited consolidated financial statements.
The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ICU MEDICAL, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
 (In thousands, except per share data)

	Three months ended March 31,	
	2018	2017
REVENUE:		
Net sales	\$372,033	\$231,788
Other	—	15,951
TOTAL REVENUE	372,033	247,739
COST OF GOODS SOLD	223,032	158,794
GROSS PROFIT	149,001	88,945
OPERATING EXPENSES:		
Selling, general and administrative	86,997	64,886
Research and development	12,586	11,641
Restructuring, strategic transaction and integration	21,569	29,401